Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical Company has received approval for an additional indication of concomitant therapy with biguanides for Actos, medicine for type 2 diabetes, from the Ministry of Health, Labour and Welfare in Japan.
Subscribe to our email newsletter
According to the company, Actos directly targets insulin resistance, a condition characterized in patients with type 2 diabetes, by improving the sensitivity to insulin mainly in the muscles, fat cells and the liver. Biguanides act primarily by reducing the amount of glucose produced by the liver.
In a randomized, double-blind, comparative study, in which the clinical usefulness of biguanides monotherapy was compared with that of Actos/biguanides concomitant therapy, the latter showed a statistically significant difference in improving HbA1c – an indicator of glycemic control – without increasing the risk of hypoglycemia.
In addition to the currently authorized concomitant therapy with sulfonylurea or alpha-GI, this additional indication for Actos of concomitant therapy with biguanides provides a further option to pursue superior glycemic control, the company said.